Search for: All records

Abstract In NMR experiments, it is crucial to control the temperature of the sample, especially when measuring kinetic parameters. Usually, it takes 2 to 5 min for the temperature of the sample inside the NMR probe to stabilize at a fixed value set for the experiment. However, the NMR sample tubes are flame‐sealed in some cases, such as when working with volatile solvents, atmosphere‐sensitive samples, or calibration samples for long‐term use. When these samples are placed inside the NMR probe, the spectrometer controls the lower portion (liquid phase) of the NMR sample tube with a gas flow at a fixed temperature, while the upper portion (vapor) is at ambient temperature. This probe design creates a unique temperature gradient across the sample, leading to vapor pressure build‐up, particularly inside a sealed NMR tube. By analyzing the temperature‐dependent spectral line shape changes of a chemical exchange process, we report that under standard experimental conditions, the sample temperature can take up to 2 to 3 h (instead of minutes) to stabilize. The time scale of the liquid–vapor equilibrium process is much slower, with a half‐life exceeding 35 min, in contrast to the 2‐min duration required to obtain each spectrum. This phenomenon is exclusively due to the liquid–vapor equilibrium process of the flame‐sealed NMR tube and is not observable otherwise. 

Glioblastoma (GBM) is the most aggressive cancer originating in the brain, but unfortunately combination treatments with resection, radiation, and chemotherapy are relatively ineffective. Therefore, novel methods of adjuvant therapy are critically needed. Cyclotides are plant-derived circular peptides that chemosensitize drug-resistant breast cancer to doxorubicin. We analyzed naturally occurring and synthetic cyclotides (Cycloviolacin O3, Cycloviolacin O19, natural Kalata B1, synthetic Kalata B1, and Vitri E) alone and in co-exposure treatments with the drug temozolomide (TMZ) in human glioblastoma cells. The cyclotides were identified by UPLC-PDA and HPLC-UV. The synthetic Kalata B1 sequence was verified with orbitrap LC-MS, and structural confirmation was provided by NMR spectroscopy. The cyclotides displayed dose-dependent cytotoxicity (IC50 values 2.4–21.1 µM) both alone and as chemosensitizers of U-87 MG and T 98 cells to TMZ. In fact, a 16-fold lower concentration of TMZ (100 µM) was needed for significant cytotoxicity in U-87 MG cells co-exposed to synthetic Kalata B (0.5 µM). Similarly, a 15-fold lower concentration of TMZ (75 µM) was required for a significant reduction in cell viability in T 98 cells co-exposed to synthetic Kalata B1 (0.25 µM). Kalata B1 remained stable in human serum stability assays. The data support the assertion that cyclotides may chemosensitize glioblastoma cells to TMZ.